Autopsy report · NCT00090675

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

“No patients randomised”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

ZD1839

Participants

0

Trials that died the same way

• Hepatic Mitochondrial Function in Sepsis
  “no patients to include” (78% match in meaning)
• Diagnostic Performance of 3T MRI T2 Mapping Technique in Chondro-labral Pathology of the Hip, Correlated With Intraoperative Arthroscopic Findings: Interventional Diagnostic Technique Validation Study (HPI MRI 3T)
  “No patients” (77% match in meaning)
• Fetoscopic Tracheal Balloon Occlusion in Unborns With Severe Congenital Diaphragmatic Hernia - EUROTRIAL I
  “No patients could be recruited and randomized due to other center offering backdoor for treatment.” (76% match in meaning)
• Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas
  “Was not able to recruit patients for randomization.” (75% match in meaning)
• Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.
  “no patients recruited” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.